Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	28.66B +289.8%
Revenue (ttm)	6.74B +18.9%
Net Income	573.25M -75.1%
EPS	6.47 -79.4%
Shares Out	n/a
PE Ratio	50.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,450
Open	335.80
Previous Close	333.25
Day's Range	325.15 - 337.60
52-Week Range	87.00 - 350.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,246
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In fiscal year 2026, Ind-Swift Laboratories's revenue was 6.41 billion, an increase of 14.17% compared to the previous year's 5.62 billion. Earnings were 414.15 million, a decrease of -83.47%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error